Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

372

Participants

Timeline

Start Date

February 9, 2016

Primary Completion Date

September 22, 2020

Study Completion Date

September 22, 2020

Conditions
Parkinson Disease
Interventions
DRUG

Deferiprone

15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.

DRUG

Placebo

the placebo twice daily morning and evening. The treatment lasts nine months

Trial Locations (25)

Unknown

Medizinische Universitat Innsbruck, Innsbruck

Charles University, Prague

Univerzita Karlova V Praze, Prague

CHU Pellegrin, Bordeaux

Hôpital Wertheimer, Bron

Hôpital Montpied, Clermont-Ferrand

Hôpital Salengro, CHRU, Lille

CHU la TIMONE, Marseille

AP-HP, Hôpital Pitié-Salpêtrière, Paris

CHU de Strasbourg, Hôpital de Hautepierre, Strasbourg

Chu Purpan, Toulouse

University Hospital, Saarland University, Homburg

Christian-albrechts universität zu kiel, Kiel

Klinik und Poliklinik für Neurologie der Universitätsmedizin Rostock, Rostock

Acadamic central center, Amsterdam, Amsterdam

Radboud university medical center, Nijmegen

Centro Hospitalar e universitario de Coimbra, Coimbra

Centro Hospitalar do Alto Ave, Guimarães

Centro Hospitalar Lisboa Norte, Lisbon

Hospital Clinic Universitari de Barcelona, Barcelona

Hospital de Bellvitge, Barcelona

Hospital de la Santa Creu i Sant Pau, Barcelona

Cambridge University Hospital, Cambridge

University of Glasgow, Glasgow

Newcastle University, Newcastle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

European Commission

OTHER

collaborator

ApoPharma

INDUSTRY

lead

University Hospital, Lille

OTHER

NCT02655315 - Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease | Biotech Hunter | Biotech Hunter